Side-effects: side-effects are common, and can include nausea, vomiting, bowel habit changes and reflux
A: Current trial data suggests orforglipron may produce around 9% to 10% body weight reduction in some populations, while injectable semaglutide has shown higher average weight-loss outcomes in longer trials
See: Both tirzepatide (thyroid tumors) and semaglutide (cancer) are at risk for thyroid cancer
By activating this receptor, semaglutide can help reduce appetite and increase feelings of fullness, leading to weight loss
The body often adjusts to the medication over several weeks, though individual experiences vary
This fatty tissue has a rich network of blood vessels that allows for steady, controlled absorption of the medication over several days